6541 Stock Overview
A biopharmaceutical company, researches, develops, manufactures, and sells biosimilar products in Taiwan and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Tanvex BioPharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$68.20 |
| 52 Week High | NT$80.00 |
| 52 Week Low | NT$35.05 |
| Beta | 0.37 |
| 11 Month Change | -2.71% |
| 3 Month Change | 9.65% |
| 1 Year Change | 11.62% |
| 33 Year Change | -59.23% |
| 5 Year Change | -59.38% |
| Change since IPO | -82.36% |
Recent News & Updates
Shareholder Returns
| 6541 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 7.1% | -0.5% | 2.3% |
| 1Y | 11.6% | 10.8% | 41.0% |
Return vs Industry: 6541 matched the TW Biotechs industry which returned 10.8% over the past year.
Return vs Market: 6541 underperformed the TW Market which returned 41% over the past year.
Price Volatility
| 6541 volatility | |
|---|---|
| 6541 Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in TW Market | 9.2% |
| 10% least volatile stocks in TW Market | 3.0% |
Stable Share Price: 6541's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 6541's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 149 | Stephen Lam | www.tanvex.com |
Tanvex BioPharma, Inc., a biopharmaceutical company, researches, develops, manufactures, and sells biosimilar products in Taiwan and the United States. It focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company’s products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial.
Tanvex BioPharma, Inc. Fundamentals Summary
| 6541 fundamental statistics | |
|---|---|
| Market cap | NT$11.19b |
| Earnings (TTM) | -NT$1.81b |
| Revenue (TTM) | NT$34.56m |
323.7x
P/S Ratio-6.2x
P/E RatioIs 6541 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6541 income statement (TTM) | |
|---|---|
| Revenue | NT$34.56m |
| Cost of Revenue | NT$26.20m |
| Gross Profit | NT$8.35m |
| Other Expenses | NT$1.82b |
| Earnings | -NT$1.81b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.02 |
| Gross Margin | 24.17% |
| Net Profit Margin | -5,232.64% |
| Debt/Equity Ratio | 0% |
How did 6541 perform over the long term?
See historical performance and comparison